5 results about "Suspension Dosage Form" patented technology

The present invention relates to a powder for an edaravone oral suspension dosage form. The invention also relates to providing patient compliant, economical and technically advanced dosage forms over existing dosage forms. In addition, compared with the prior art, the patient compliance edaravone preparation prepared according to the invention is proved to be higher in solubility and stability. In addition, the present invention also provides a powder composition for oral suspension prepared by an improved method that is relatively simple, easy for commercial production, and replicable in function.

An immediate-release liquid oral suspension of Eslicarbazepine Acetate, containing between about 5 to about 10 g of active ingredient per 100 mL, along with carbomer homopolymer and microcrystalline cellulose as viscosity modifying agents. It may further comprise, parabens as antimicrobial agent, sucralose as a sweetener, and polyethylene glycol 8 stearate as a surfactant. The suspension is designed to provide bioequivalence to marketed Eslicarbazepine Acetate tablets, ensuring rapid drug release and stability over extended storage periods. The pH is adjusted to 3.0-6.5 to maintain stability, with impurities remaining under 0.05% of the eslicarbazepine content after stress storage conditions. This formulation offers an alternative to solid dosage forms for patients with partial-onset seizures.

The present invention relates to oral pharmaceutical suspension dosage form of Lapatinib and process of manufacturing thereof. The invention relates to providing patient-compliant, economical and technically advanced dosage form over existing dosage form.

The present invention belongs to the technical field of biomedicine, and discloses a bionic nanoparticle suspension dosage form based on orthoester compounds and a preparation method thereof. The bionic nanoparticle suspension dosage form includes liquid excipients, as well as a photosensitizer and bionic nanoparticles dispersed in the liquid excipients. In the present invention, an orthoester compound represented by Formula I is used as the liquid excipient, and the bionic nanoparticles and the photosensitizer are simultaneously introduced into OE to obtain a bionic nanoparticle suspension dosage form with multiple anti-tumor mechanisms. Among them, the bionic nanoparticles are nano-drugs encapsulated by cancer cell membrane vesicles, and through the cancer cell membrane bionic technology, the homologous targeting function provided by the cancer cell membrane is utilized to significantly improve the active targeting and cellular uptake of the nano-drugs. Formula I:

The present disclosure provides an oral suspension of allopurinol suitable for administration to pediatric, geriatric patients, as well as to patients experiencing difficulty in swallowing solid dosage forms. The suspension is stable, palatable and safer compared to compounded suspensions of allopurinol. The suspension dosage form of allopurinol also allows for a more accurate dosing. The suspension is stable for at least 24 months at room temperature, demonstrating low impurity formation under storage conditions.